Antiprogestins for contraception?

Seminars in Reproductive Medicine

Volumn 23, Issue 1, 2005, Pages 92-100

  Von Hertzen, Helena ^a   Van Look, Paul F A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiprogestins; Contraception; Emergency contraception; Mifepristone

Indexed keywords

ANTIGESTAGEN; DESOGESTREL; ESTRADIOL; FOLLITROPIN; GESTAGEN; LUTEINIZING HORMONE; MIFEPRISTONE; PROGESTERONE;

AMENORRHEA; ANOVULATION; CONDOM; CONTRACEPTION; DRUG EFFICACY; ECHOGRAPHY; EMBRYO TRANSFER; EMERGENCY CONTRACEPTION; FAMILY PLANNING; FERTILIZATION; HUMAN; MENSTRUAL CYCLE; NONHUMAN; OVULATION INHIBITION; PILL; PREGNANCY; REPRODUCTION; REVIEW; TARGET ORGAN; UTERINE TUBE; UTERUS CONTRACTILITY; VAGINA BLEEDING;

ABORTIFACIENT AGENTS; ANIMALS; CONTRACEPTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERTILITY; HORMONE ANTAGONISTS; HUMANS; LUTEAL PHASE; MENSTRUATION DISTURBANCES; PROGESTINS;

EID: 14744298340     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864037     Document Type: Review

References (49)

1. United Nations. World Contraceptive Use 2003. New York: United Nations, 2004
2. Shah IH. Perspectives of users and potential users on methods of fertility regulation. In: Puri CP, Van Look PFA, eds. Sexual and Reproductive Health - Recent Advances and Future Directions. Vol II. New Delhi: New Age International (P) Ltd.; 2001:45-92
3. World Health Organization. Improving Access to Quality Care in Family Planning - Medical Eligibility Criteria for Contraceptive Use, 3rd ed. Geneva: Department of Reproductive Health and Research, World Health Organization; 2004
4. Wang C, Sinha-Hikim A, Leung A. The anti-progestin CDB 2914 has no antifertility effect in male rats. Contraception 1995;51:215-218
5. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Merriam GR, Loriaux DL. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotrophin surge and ovulation. J Clin Endocrinol Metab 1992;74:565-570
6. Gemzell-Danielsson K, Swahn ML, Westlund P, Johannisson E, Seppälä M, Bygdeman M. Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1997;12:124-131
7. Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab 1987;65:1135-1140
8. Chen XL, Xiao BL. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception 1997;56:175-180
9. Croxatto HB, Salvatierra AM, Fuentealba B, Zurth C, Beier S. Effect of the antiprogestin onapristone on follicular growth in women. Hum Reprod 1994;9:1442-1447
10. Stratton P, Hartog B, Hajizadeh N, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092-1099
11. Roblero LS, Croxatto HB. Effects of RU 486 on development and implantation of rat embryos. Mol Reprod Dev 1991;29:342-346
12. Borman SM, Chwalisz K, Stouffer RL, Zelinski-Wooten MB. Chronic low-dose antiprogestin impairs preimplantation embryogenesis, but not oocyte nuclear maturation or fertilization in rhesus monkeys. Steroids 2003;68:1041-1051
13. Heikinheimo O, Croxatto H, Salvatierra AM, Chang CC, Luukkainen T, Lahteenmaki P. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans. Hum Reprod 1987;2:645-648
14. Heikinheimo O, Kekkonen R, Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003;68:421-426
15. Heikinheimo O, Kekkonen R. Dose-response relationship of RU 486. Ann Med 1993;25:71-76
16. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-537
17. Passaro DP, Piquion J, Mullen N, et al. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod 2003;18:1820-1827
18. Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002;124:167-172
19. Marions L, Viski S, Gemzell-Danielsson K, et al. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod 1999;14:2788-2790
20. Croxatto HB, Kovacs L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998;13:793-798
21. Brown A, Cheng L, Lin SQ, Baird D. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
22. Gemzell-Danielsson K, Westlund P, Johannisson E, Swahn ML, Bygdeman M, Seppala M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996;11:256-264
23. Marions L, Gemzell-Danielsson K, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998;70:813-816
24. Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O. Response to intermittent RU 486 in women. Fertil Steril 1993;59:971-975
25. Godfrey EM, Mawson JT, Stanwood NL, Fielding SL, Schaff EA. Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study. Contraception 2004;70:41-46
26. Cheng J, Weng LJ, Han XJ. Study on weekly low doses of mifepristone for contraception. Chinese Journal of Obstetrics and Gynecology 2001;36:424-427
27. Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin. Fertil Steril 1990;53:747-750
28. Kekkonen R, Lähteenmäki P, Luukkainen T, Tuominen J. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril 1993;60:610-615
29. Kekkonen R, Croxatto HB, Lähteenmäki P, Salvatierra AM, Tuominen J. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation. Hum Reprod 1995;10:287-292
30. Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P. Effects of a sequential regimen of mifepristone- medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception 1996;54:79-86
31. Croxatto HB, Salvatierra AM, Fuentealba B, Massai R. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum Reprod 1998;13:3297-3302
32. Massai R, Forcelledo ML, Quinteros E, Fuentealba B, Croxatto HB. Anticoncepción oral libre de estrógenos: Regimen secuencial antiprogestina-progestina. Cuban Journal of Public Health 2003;29(suppl 1):R104
33. Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new antiprogestogen. Hum Reprod 2002;17:2588-2593
34. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-1972
35. Massai MR, Pavez M, Fuentealba B, Croxatto HB, d'Arcangues C. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70:47-54
36. Swahn ML, Johannisson E, Daniore V, de la Torre B, Bygdeman M. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Hum Reprod 1988;3:915-921
37. Gemzell K, Swahn ML, Bygdeman M. Regulation of non-pregnant human uterine contractility. Effect of antihormones. Contraception 1990;42:323-335
38. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-873
39. Hapangama DK, Brown A, Glasier A, Baird DT. Feasibility of administering mifepistone as a once a month contraceptive pill. Hum Reprod 2001;16:1145-1150
40. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-1044
41. Webb AMC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception. BMJ 1992;305:927-931
42. Ashok PW, Stalder C, Wagaarachchi PT, Flett G, Melvon L, Templeton A. A randomized study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG 2002;109:553-560
43. Croxatto HB, Salvatierra AM, Fuentealba B, Leiva L. Follicle stimulating hormone-granulosa cell axis involvement in the antifolliculotrophic effect of low dose mifepristone (RU486). Hum Reprod 1995;10:1987-1991
44. Graham RA, Li TC, Seif MW, Aplin JD, Cooke ID. The effects of the antiprogesterone RU486 (Mifepristone) on an endometrial secretory glycan: an immunocytochemical study. Fertil Steril 1991;55:1132-1136
45. Task Force on Postovulatory Methods of Fertility. Regulation Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 1999;353:697-702
46. Xiao BL, von Hertzen H, Zhao H, Piaggio G. A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum Reprod 2002;17:3084-3089
47. Piaggio G, Zhao H, von Hertzen H, Xiao BL, Cheng L. Combined estimates of effectiveness of mifepristone 10 mg in emergency contraception. Contraception 2003;68:439-446
48. von Hertzen H, Piaggio G, Ding JH, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2002;360:1803-1810
49. Cheng L, Gulmezoglu AM, Ezcurra E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2004;3:CD001324